VC
CAMP icon

Vivo Capital’s CAMP4 Therapeutics CAMP Stock Holding History

Vivo Capital’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.7M Hold
4,246,568
– – 1.56% 23
2025
Q4 		$26M Buy
4,246,568
+325,000
+8% +$1.38M 1.68% 20
2025
Q3 		$11.8M Buy
+3,921,568
New +$7.26M 0.95% 28

Other funds holding CAMP

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vivo Capital's CAMP Position: Q1 2026 in Review

Vivo Capital held its CAMP4 Therapeutics (CAMP) position steady in Q1 2026 at 4,246,568 shares worth $18.7M. The position accounts for 1.56% of the portfolio, ranked #23.

Vivo Capital first reported a position in CAMP in Q3 2025 and has held it in 3 quarters since. The position peaked at $26M in Q4 2025. 46 funds tracked by Wall St. Rank hold CAMP as of Q1 2026.

  • Vivo Capital held 4,246,568 shares of CAMP4 Therapeutics worth $18.7M as of Q1 2026.
  • Vivo Capital left its CAMP4 Therapeutics share count unchanged in Q1 2026.
  • CAMP4 Therapeutics made up 1.56% of Vivo Capital's portfolio in Q1 2026, its #23 holding.
  • Vivo Capital first reported a position in CAMP4 Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Vivo Capital's CAMP4 Therapeutics position peaked at $26M in Q4 2025.
  • 46 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.